Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Total Non-Current Liabilities (2019 - 2021)

Historic Total Non-Current Liabilities for IDEAYA Biosciences (IDYA) over the last 3 years, with Q3 2021 value amounting to $81.8 million.

  • IDEAYA Biosciences' Total Non-Current Liabilities fell 2278.02% to $81.8 million in Q3 2021 from the same period last year, while for Sep 2021 it was $81.8 million, marking a year-over-year decrease of 2278.02%. This contributed to the annual value of $100.0 million for FY2020, which is 69559.96% up from last year.
  • Latest data reveals that IDEAYA Biosciences reported Total Non-Current Liabilities of $81.8 million as of Q3 2021, which was down 2278.02% from $88.1 million recorded in Q2 2021.
  • IDEAYA Biosciences' 5-year Total Non-Current Liabilities high stood at $105.9 million for Q3 2020, and its period low was $11.9 million during Q3 2019.
  • For the 3-year period, IDEAYA Biosciences' Total Non-Current Liabilities averaged around $53.1 million, with its median value being $47.2 million (2019).
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first surged by 79230.19% in 2020, then plummeted by 2278.02% in 2021.
  • Over the past 3 years, IDEAYA Biosciences' Total Non-Current Liabilities (Quarter) stood at $12.6 million in 2019, then skyrocketed by 695.6% to $100.0 million in 2020, then decreased by 18.18% to $81.8 million in 2021.
  • Its Total Non-Current Liabilities stands at $81.8 million for Q3 2021, versus $88.1 million for Q2 2021 and $93.0 million for Q1 2021.